46.88
price down icon1.55%   -0.74
after-market Handel nachbörslich: 46.89 0.010 +0.02%
loading
Schlusskurs vom Vortag:
$47.62
Offen:
$47
24-Stunden-Volumen:
22.41M
Relative Volume:
1.65
Marktkapitalisierung:
$100.96B
Einnahmen:
$47.64B
Nettoeinkommen (Verlust:
$5.42B
KGV:
17.56
EPS:
2.67
Netto-Cashflow:
$13.09B
1W Leistung:
-5.50%
1M Leistung:
-11.66%
6M Leistung:
-13.41%
1J Leistung:
+7.35%
1-Tages-Spanne:
Value
$46.52
$47.40
1-Wochen-Bereich:
Value
$46.52
$50.65
52-Wochen-Spanne:
Value
$39.35
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
Firmenname
Bristol Myers Squibb Co
Name
Telefon
(609) 252-4621
Name
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
Mitarbeiter
34,100
Name
Twitter
@BMSNEWS
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
BMY's Discussions on Twitter

Vergleichen Sie BMY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
46.88 100.96B 47.64B 5.42B 13.09B 2.67
Drug Manufacturers - General icon
LLY
Lilly Eli Co
751.45 681.85B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
155.66 370.90B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.58 342.01B 57.37B 4.20B 17.83B 2.35
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.85 291.20B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
110.13 219.89B 53.22B 12.86B 14.85B 6.39

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-22 Eingeleitet Cantor Fitzgerald Neutral
2025-04-22 Eingeleitet Piper Sandler Overweight
2024-12-16 Hochstufung Jefferies Hold → Buy
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-11-15 Eingeleitet Wolfe Research Peer Perform
2024-11-13 Hochstufung Daiwa Securities Neutral → Outperform
2024-11-12 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-25 Herabstufung Citigroup Buy → Neutral
2024-10-17 Eingeleitet Bernstein Mkt Perform
2024-07-29 Herabstufung Barclays Overweight → Equal Weight
2024-03-11 Herabstufung Societe Generale Buy → Hold
2024-02-06 Herabstufung Redburn Atlantic Buy → Neutral
2024-01-03 Herabstufung BofA Securities Buy → Neutral
2023-11-15 Herabstufung Cantor Fitzgerald Overweight → Neutral
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-11-02 Herabstufung Daiwa Securities Outperform → Neutral
2023-10-27 Herabstufung BMO Capital Markets Outperform → Market Perform
2023-10-27 Hochstufung HSBC Securities Reduce → Hold
2023-10-27 Herabstufung William Blair Outperform → Mkt Perform
2023-10-20 Fortgesetzt UBS Neutral
2023-07-14 Eingeleitet HSBC Securities Reduce
2023-07-10 Eingeleitet SVB Securities Market Perform
2023-06-28 Eingeleitet Daiwa Securities Outperform
2023-03-06 Eingeleitet Jefferies Hold
2023-01-17 Eingeleitet Cantor Fitzgerald Overweight
2022-11-18 Eingeleitet Credit Suisse Neutral
2022-10-10 Herabstufung Guggenheim Buy → Neutral
2022-09-14 Herabstufung Berenberg Buy → Hold
2022-06-03 Herabstufung Raymond James Outperform → Mkt Perform
2022-04-06 Fortgesetzt Morgan Stanley Underweight
2021-12-17 Eingeleitet Goldman Buy
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-11-01 Herabstufung Argus Buy → Hold
2021-07-27 Fortgesetzt Truist Buy
2021-04-30 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-04-13 Hochstufung Truist Hold → Buy
2020-11-16 Hochstufung Societe Generale Hold → Buy
2020-11-10 Fortgesetzt Bernstein Mkt Perform
2020-11-06 Herabstufung Gabelli & Co Buy → Hold
2020-10-19 Hochstufung Guggenheim Neutral → Buy
2020-09-29 Eingeleitet Berenberg Buy
2020-07-28 Eingeleitet Raymond James Outperform
2020-04-02 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-03-23 Herabstufung Societe Generale Buy → Hold
2020-02-27 Eingeleitet Barclays Equal Weight
2020-01-06 Fortgesetzt Citigroup Buy
2019-12-13 Hochstufung Argus Hold → Buy
2019-11-22 Fortgesetzt Morgan Stanley Equal-Weight
2019-10-17 Fortgesetzt BofA/Merrill Buy
2019-08-14 Hochstufung Atlantic Equities Neutral → Overweight
2019-05-28 Eingeleitet Goldman Buy
2019-05-20 Herabstufung Argus Buy → Hold
2019-05-03 Hochstufung Barclays Equal Weight → Overweight
2019-05-03 Fortgesetzt JP Morgan Overweight
2019-01-15 Hochstufung Societe Generale Sell → Buy
2018-10-22 Herabstufung Citigroup Buy → Neutral
Alle ansehen

Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten

pulisher
May 08, 2025

Neuroendocrine Tumor Treatment Market: Investment Analysis & - openPR.com

May 08, 2025
pulisher
May 08, 2025

Bristol Myers Squibb Co. Becomes Oversold - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Bristol Myers Squibb Co. Named Top Dividend Stock With Insider Buying and 5.21% Yield (BMY) - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Urothelial Carcinoma Market on Track for Major Expansion by 2034, According to DelveInsight | Infinity, QED Therapeutics, BeiGene, Eli Lilly, Roche, UroGen, NektarTherapeutics, BMS, Incyte, Abbisko - Barchart.com

May 08, 2025
pulisher
May 08, 2025

Improving Access to Care by Strengthening Local Health System Capacity - CSRwire

May 08, 2025
pulisher
May 08, 2025

The Zacks Analyst Blog Highlights Verizon Communications, Bristol-Myers Squibb, Canadian Pacific and Nova LifeStyle - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - BioSpace

May 08, 2025
pulisher
May 08, 2025

Top Research Reports for Verizon Communications, Bristol-Myers Squibb & Canadian Pacific - MSN

May 08, 2025
pulisher
May 07, 2025

Bristol Myers Squibb to Invest $40B in the U.S. - Contract Pharma

May 07, 2025
pulisher
May 07, 2025

Advanced Renal Cell Carcinoma Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Pfizer, AbbVie, Bristol-Myers Squibb, Abbott, Takeda, Amgen, Novartis, AVEO Pharma, Calithera - The Globe and Mail

May 07, 2025
pulisher
May 07, 2025

Multiple Myeloma Market Set to Grow Substantially Through 2034, DelveInsight Projects | Johnson & Johnson Innovative Medicine, Bristol Myers Squibb, Regeneron, AbbVie and Roche, Janssen Pharma - Barchart.com

May 07, 2025
pulisher
May 07, 2025

Bristol Myers Squibb appoints new general counsel - | Governance Intelligence

May 07, 2025
pulisher
May 06, 2025

Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MSN

May 06, 2025
pulisher
May 06, 2025

BMS Commits $40B over Five Years to U.S. R&D, Manufacturing - Genetic Engineering and Biotechnology News

May 06, 2025
pulisher
May 06, 2025

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight - Benzinga

May 06, 2025
pulisher
May 06, 2025

Bristol-Myers GC Hands Over Legal Department To Successor - Law360

May 06, 2025
pulisher
May 06, 2025

Bristol Myers Squibb names new executive vice president By Investing.com - Investing.com Canada

May 06, 2025
pulisher
May 06, 2025

Bristol Myers (BMY) Experiences Increased Bearish Activity in Op - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Bristol Myers (BMY) Experiences Increased Bearish Activity in Options Market | BMY Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Bristol Myers (BMY) Unveils $40 Billion Investment in U.S. Over Five Years | BMY Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Bristol Myers Squibb Appoints Cari Gallman as EVP, General Counsel and Chief Policy Officer - citybiz

May 06, 2025
pulisher
May 06, 2025

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga

May 06, 2025
pulisher
May 06, 2025

Bristol Myers (BMY) Appoints Cari Gallman as New General Counsel - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours - PMLiVE

May 06, 2025
pulisher
May 06, 2025

Bristol Myers Squibb announces $40bn US investment plan over five years - Yahoo Finance

May 06, 2025
pulisher
May 06, 2025

Bristol Myers Squibb names new executive vice president - Investing.com

May 06, 2025
pulisher
May 06, 2025

Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer - Quantisnow

May 06, 2025
pulisher
May 06, 2025

Bristol Myers to invest $40 billion in the US over 5 years | Business Information & News | FE - Westlaw Today

May 06, 2025
pulisher
May 05, 2025

Bristol Myers to invest $40 billion in the US over 5 years - Reuters

May 05, 2025
pulisher
May 05, 2025

Bristol Myers to invest $51.6 billion in the US over 5 years - The Straits Times

May 05, 2025
pulisher
May 05, 2025

Company with deep NJ roots plans hundreds of more layoffs out of New Jersey - New Jersey 101.5

May 05, 2025
pulisher
May 05, 2025

Bristol Myers to invest $40 billion in the US over 5 years, CEO says - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

Bristol Myers Promises $40 Billion US Investment Over Five Years - MSN

May 05, 2025
pulisher
May 05, 2025

Bristol Myers Squibb Laying Off 500+ Employees From Lawrence Township Office - dailyvoice.com

May 05, 2025
pulisher
May 05, 2025

Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace

May 05, 2025
pulisher
May 05, 2025

Was Jim Cramer Right About Bristol-Myers Squibb Company (BMY)? - Insider Monkey

May 05, 2025
pulisher
May 03, 2025

Bristol-Myers Squibb (BMY) Faces Valuation Concerns - GuruFocus

May 03, 2025
pulisher
May 02, 2025

Are Wall Street Analysts Bullish on Bristol-Myers Stock? - MSN

May 02, 2025
pulisher
May 01, 2025

Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug - Insider Monkey

May 01, 2025
pulisher
May 01, 2025

MHRA approval for BMS’ SC Opdivo - The Pharma Letter

May 01, 2025
pulisher
May 01, 2025

Bristol-Myers Squibb's (NYSE:BMY) Strong Earnings Are Of Good Quality - Yahoo Finance

May 01, 2025
pulisher
Apr 30, 2025

BMY Gains UK Approval for Faster Nivolumab Injection | BMY Stock News - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Piper Sandler Raises Price Target for Bristol Myers (BMY) to $66 | BMY Stock News - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Bristol Myers Squibb: innovating oncology care - MSN

Apr 30, 2025
pulisher
Apr 30, 2025

Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.

Apr 30, 2025
pulisher
Apr 29, 2025

Is Bristol-Myers Squibb Company (BMY) the Best Long-Term Dividend Stock to Buy According to Billionaires? - Insider Monkey

Apr 29, 2025
pulisher
Apr 29, 2025

BMY: Bristol Myers' Chief Medical Officer Acquires Additional Sh - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance

Apr 29, 2025
pulisher
Apr 29, 2025

Our impact - Bristol Myers Squibb

Apr 29, 2025
pulisher
Apr 28, 2025

Jim Cramer is Recommending This Dividend Stock With 5% Yield for ‘Good Protection’ - Yahoo Finance

Apr 28, 2025
pulisher
Apr 28, 2025

HSBC Adjusts Price Target for Bristol Myers (BMY) Amid Tariff Co - GuruFocus

Apr 28, 2025

Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$98.16
price down icon 0.75%
drug_manufacturers_general SNY
$52.13
price down icon 0.27%
drug_manufacturers_general PFE
$22.97
price up icon 0.79%
$272.05
price down icon 1.37%
drug_manufacturers_general MRK
$77.65
price down icon 1.86%
drug_manufacturers_general NVS
$110.13
price down icon 1.41%
Kapitalisierung:     |  Volumen (24h):